BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 16232003)

  • 1. Impact of 3-tier pharmacy benefit design and increased consumer cost-sharing on drug utilization.
    Landsman PB; Yu W; Liu X; Teutsch SM; Berger ML
    Am J Manag Care; 2005 Oct; 11(10):621-8. PubMed ID: 16232003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of incentive-based formularies on prescription-drug utilization and spending.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Frank RG
    N Engl J Med; 2003 Dec; 349(23):2224-32. PubMed ID: 14657430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
    Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
    Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of mail-service and retail community pharmacy claims in 5 prescription benefit plans.
    Clark BE; Siracuse MV; Garis RI
    Res Social Adm Pharm; 2009 Jun; 5(2):133-42. PubMed ID: 19524861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance.
    Klepser DG; Huether JR; Handke LJ; Williams CE
    J Manag Care Pharm; 2007; 13(9):765-77. PubMed ID: 18062728
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of tiered prescription copayments on the use of preferred brand medications.
    Rector TS; Finch MD; Danzon PM; Pauly MV; Manda BS
    Med Care; 2003 Mar; 41(3):398-406. PubMed ID: 12618643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The implications of choice: prescribing generic or preferred pharmaceuticals improves medication adherence for chronic conditions.
    Shrank WH; Hoang T; Ettner SL; Glassman PA; Nair K; DeLapp D; Dirstine J; Avorn J; Asch SM
    Arch Intern Med; 2006 Feb; 166(3):332-7. PubMed ID: 16476874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of the use and costs of physician office visits and prescription drugs to travel distance and increases in member cost share.
    Cecil WT; Barnes J; Shea T; Coulter SL
    J Manag Care Pharm; 2006 Oct; 12(8):665-76. PubMed ID: 17269845
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of copayments and generic substitution on the use and costs of prescription drugs.
    Smith DG
    Inquiry; 1993; 30(2):189-98. PubMed ID: 8314607
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lowering copayments: impact of simvastatin patent expiration on patient adherence.
    Sedjo RL; Cox ER
    Am J Manag Care; 2008 Dec; 14(12):813-8. PubMed ID: 19067498
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Controlling prescription drug expenditures: a report of success.
    Miller DP; Furberg CD; Small RH; Millman FM; Ambrosius WT; Harshbarger JS; Ohl CA
    Am J Manag Care; 2007 Aug; 13(8):473-80. PubMed ID: 17685828
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
    Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
    Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incentive formularies and changes in prescription drug spending.
    Landon BE; Rosenthal MB; Normand SL; Spettell C; Lessler A; Underwood HR; Newhouse JP
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):360-9. PubMed ID: 17567237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
    Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
    Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing prescription drug costs.
    Sica JM
    Empl Benefits J; 2001 Mar; 26(1):35-40. PubMed ID: 11272515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association of consumer cost-sharing and direct-to-consumer advertising with prescription drug use.
    Hansen RA; Schommer JC; Cline RR; Hadsall RS; Schondelmeyer SW; Nyman JA
    Res Social Adm Pharm; 2005 Jun; 1(2):139-57. PubMed ID: 17138472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of patient and plan design factors on switching to preferred statin therapy.
    Cox ER; Kulkarni A; Henderson R
    Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between generic and preferred-brand prescription copayment differentials and generic fill rate.
    Mager DE; Cox ER
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):347-52. PubMed ID: 17567235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of 3-tier formularies on drug treatment of attention-deficit/hyperactivity disorder in children.
    Huskamp HA; Deverka PA; Epstein AM; Epstein RS; McGuigan KA; Muriel AC; Frank RG
    Arch Gen Psychiatry; 2005 Apr; 62(4):435-41. PubMed ID: 15809411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effective strategies for managing pharmacy benefits.
    Jacobson D
    Healthc Financ Manage; 2001 Mar; 55(3):41-2. PubMed ID: 11258270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.